Login to Your Account

Santarus Makes Phase III HAE, Pharming for Harvest in Acute

By Randy Osborne and Cormac Sheridan
Staff Writers

Wednesday, November 14, 2012
Poised to wade into a crowded field of drugs for hereditary angioedema (HAE), Santarus Inc. and partner Pharming Group NV said last week the pivotal Phase III study with the C1 esterase inhibitor Ruconest for acute HAE attacks met the primary endpoint of time to beginning of symptom relief.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription